Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM) -- Ignore unavailable to you. Want to Upgrade?

To: MikeM54321 who wrote (190)	4/21/1998 4:56:00 PM
From: SJS	Respond to of 3044

Try this post: exchange2000.com

To: MikeM54321 who wrote (190)	4/21/1998 5:38:00 PM
From: Biomaven	Respond to of 3044

Mike, If you take a look at the latest Proxy, you'll see that Lander is the Whitehead Director. He's remains a director of and consultant to MLNM. According to the sales figures posted and the Proxy numbers, he must be about all out of shares by now. The stock has held up pretty well, consdiering the Lander sales, the MIT sales and also substantial dispositions by some of the early VC investors. These sales seem driven by the needs of the sellers rather than by them getting out while the getting's good. My view is that it creates a buying opportunity for the patient investor. Peter

To: MikeM54321 who wrote (190)	4/21/1998 6:01:00 PM
From: Richard Haugland	Read Replies (1) \| Respond to of 3044

It even appears that Eric Lander is trying to get some good prices during his selling. I would not be surprised then if he was selling into the rise today. Certainly the volume sellers kept this from rising to a better response to today's news. Hopefully he is almost out or totally out now.

To: MikeM54321 who wrote (190)	4/22/1998 12:37:00 AM
From: Pseudo Biologist	Read Replies (1) \| Respond to of 3044

Mike, the "particular fellow" is indeed Lander, and the paragraph you cite is consistent with what the company has said in the past. Namely, Lander cannot, according to MIT/Whitehead rules, hold stock in, and receive funding from, the same company. In last year's proxy Lander was listed as holding about 700,000 shares of MLNM; in this year's his holdings are down to 20-30K. Here is the release announcing the establishment of the genomics center with Lander as head: mlnm.com PB